BIIB vs TGTX
BIIB: A pioneer in neuroscience and immunology, Biogen is a major biotechnology company focused on addressing high-unmet medical needs in complex diseases like Alzheimer’s, Multiple Sclerosis, and SMA. TGTX: TG Therapeutics is a commercial-stage biotechnology company driving growth through its FDA-approved multiple sclerosis therapy, BRIUMVI, and an expanding pipeline of B-cell disease treatments.
Side-by-side fundamentals
| Metric | BIIB | TGTX | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $243.10 | $54.53 | |
| Market cap | $35.9B | $8.3B | |
| P/E as of 2026-10-20 | 26.14 | 19.90 | TGTX lower |
| Net margin FY2025, SEC XBRL | +13.1% | +72.6% | TGTX higher |
| Operating margin | +25.9% | +20.0% | BIIB higher |
| ROE FY2025, SEC XBRL | +7.1% | +69.0% | TGTX higher |
| ROA FY2025, SEC XBRL | +4.4% | +42.1% | TGTX higher |
| Debt / equity | 0.34 | 1.23 | BIIB lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +2.2% | +87.3% | TGTX higher |
| Revenue CAGR (3y) SEC XBRL | -0.9% | +504.9% | TGTX higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.50 | 0.66 | |
| 1-year return as of 2026-10-20 close | +65.8% | +55.3% | BIIB higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.